Helsinn to provide independent educational grant support for a satellite symposium on Delivering Chemotherapy with Confidence: New Strategies to Minim

Lugano, Switzerland, 22 September, 2014 – Helsinn Group, a company focused on building quality cancer care, today announces that it is supporting an independent educational satellite symposium on Delivering Chemotherapy With Confidence: New Strategies to Minimize Treatment-Induced Nausea and Vomiting at the 38th European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, in 2014.

Helsinn has awarded a grant to prIME oncology, a global professional Independent Medical Education organization specializing in educational activities for physicians who treat patients with cancer. prIME oncology has developed an education program for ESMO 2014 designed to improve the understanding of the basic physiology of chemotherapy-induced nausea and vomiting (CINV) and the mechanisms of action of the currently used different classes of antiemetic agents. The symposium will help to create a better appreciation of the treatment and patient variations that underpin CINV and the therapeutic options recommended by international guidelines that should be applied in routine clinical practice. It will also raise awareness of the appropriate strategies to individualize antiemetic therapy and incorporate the latest information on effective, convenient and well-tolerated antiemetic regimens for both moderately and highly emetogenic chemotherapy.